Date: 2013-10-03
Type of information: Presentation of results at a congress
phase: 2
Announcement: presentation of results at the 22nd Congress Of The European Academy Of Dermatology And Venereology
Company: Amgen (USA) AstraZeneca (UK)
Product: brodalumab (AMG 827)
Action
mechanism: Brodalumab is a highly-selective human monoclonal antibody that binds to and blocks signaling via the interleukin-17 (IL-17) receptor. The IL-17 pathway plays an important role in inducing and promoting inflammatory disease processes. Blocking inflammatory signaling at the IL-17 receptor may be beneficial in the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and potentially other immune-mediated diseases.
In April 2012, Amgen and AstraZeneca have announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen\'s clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab - AMG 827).
Disease: moderate to severe psoriasis
Therapeutic area: Autoimmune diseases – Dermatological diseases
Country:
Trial details:
Latest
news: * On October 3, 2013, Amgen And AstraZeneca, with its biologics research and development arm MedImmune, have announced the upcoming presentation of several key studies evaluating brodalumab, a human monoclonal antibody targeting the interleukin-17 (IL-17) receptor, for the treatment of moderate to severe psoriasis at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV) in Istanbul, Oct. 2-6, 2013. In October. 2012, the companies announced the start of the Phase 3 program in moderate to severe psoriasis for brodalumab. The program consists of three Phase 3 studies evaluating treatment with brodalumab compared with ustekinumab and/or placebo.
Abstracts of Interest Include:
Maintenance of Clinical Response with Long-Term Brodalumab (AMG 827) Therapy for Psoriasis: Week 96 Results from an Open-Label Extension Study (Poster IST13-0686)
Difference in Health-Related Quality of Life (HRQoL) with Increased Improvements in Psoriasis Area and Severity Index (PASI) and Maintenance of Skin Clearance (Poster 1030)
Impact of Treatment with Brodalumab on Psoriasis Symptom Severity: Use of a Novel Patient-Reported Outcome Measure, the Psoriasis Symptom Inventory (PSI) (Poster 1640)
